Krystal Biotech, Inc.

KRYS

$208.25

Name : Krystal Biotech, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $6,027,375,616.00

EPSttm : 6.68

Krystal Biotech, Inc.

$208.25

1.01%

$2.09

Float Short %

11.56

Margin Of Safety %

-9

Put/Call OI Ratio

1.73

EPS Next Q Diff

EPS Last/This Y

2.74

EPS This/Next Y

2.76

Price

208.37

Target Price

222.45

Analyst Recom

1.17

Performance Q

44.66

Relative Volume

0.99

Beta

0.48

Ticker: KRYS

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-10-20	KRYS	195.96	2.07	7.52	8070
2025-10-21	KRYS	190.76	2.52	0.42	9957
2025-10-22	KRYS	186.21	2.51	0.26	9962
2025-10-23	KRYS	186.18	2.50	0.29	9975
2025-10-24	KRYS	186.18	2.49	1.40	9979
2025-10-27	KRYS	190.2	2.49	24.67	9980
2025-10-28	KRYS	189.69	2.47	5.00	9940
2025-10-29	KRYS	184.81	2.48	0.25	9951
2025-10-30	KRYS	188.95	2.47	0.38	9958
2025-10-31	KRYS	196.99	2.46	10.67	9964
2025-11-03	KRYS	198.5	2.45	2.62	10806
2025-11-04	KRYS	203.27	2.36	0.05	10903
2025-11-05	KRYS	199.88	1.74	0.07	12129
2025-11-06	KRYS	199.68	1.70	0.59	12214
2025-11-07	KRYS	197.75	1.70	0.03	12227
2025-11-10	KRYS	199.59	1.71	1.00	12206
2025-11-11	KRYS	203	1.71	0.05	12207
2025-11-12	KRYS	203.15	1.74	1.18	12128
2025-11-13	KRYS	201.43	1.74	0.06	12131
2025-11-14	KRYS	206.16	1.74	0.34	12137
2025-11-17	KRYS	208.27	1.73	0.10	12176
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-10-20	KRYS	195.96	-13.0	190.1	4.95
2025-10-21	KRYS	190.51	-13.0	168.4	4.95
2025-10-22	KRYS	186.42	-13.0	170.2	4.95
2025-10-23	KRYS	186.28	-13.0	178.5	4.95
2025-10-24	KRYS	186.20	-13.0	178.3	4.95
2025-10-27	KRYS	190.05	-13.0	186.8	4.95
2025-10-28	KRYS	189.65	-13.0	178.3	5.08
2025-10-29	KRYS	185.00	-13.0	169.6	5.08
2025-10-30	KRYS	189.08	-13.0	187.3	5.08
2025-10-31	KRYS	197.51	-13.0	196.2	5.08
2025-11-03	KRYS	197.66	-13.0	179.1	5.08
2025-11-04	KRYS	203.04	-13.0	188.5	5.08
2025-11-05	KRYS	199.80	-13.0	172.4	5.08
2025-11-06	KRYS	199.68	-18.5	216.7	5.12
2025-11-07	KRYS	197.93	0.7	212.7	5.12
2025-11-10	KRYS	199.53	0.7	220.4	5.12
2025-11-11	KRYS	203.00	13.1	224.2	5.86
2025-11-12	KRYS	203.20	13.1	217.4	5.86
2025-11-13	KRYS	201.43	13.1	213.7	5.86
2025-11-14	KRYS	205.88	13.1	226.7	5.86
2025-11-17	KRYS	208.37	13.1	221.4	5.86
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-10-20	KRYS	-2.39	0.91	13.69
2025-10-21	KRYS	-2.39	0.91	13.69
2025-10-22	KRYS	-2.39	0.91	13.69
2025-10-23	KRYS	-2.39	0.91	13.69
2025-10-24	KRYS	-2.39	0.91	13.69
2025-10-27	KRYS	-2.39	-0.44	11.62
2025-10-28	KRYS	-2.39	-0.44	11.62
2025-10-29	KRYS	-2.39	-0.44	11.62
2025-10-30	KRYS	-2.39	-0.44	11.62
2025-10-31	KRYS	-2.39	-0.44	11.62
2025-11-03	KRYS	-2.39	-0.38	11.62
2025-11-04	KRYS	-2.39	-0.38	11.62
2025-11-05	KRYS	-2.39	-0.38	11.62
2025-11-06	KRYS	-2.39	-0.38	11.60
2025-11-07	KRYS	-2.39	-0.38	11.60
2025-11-10	KRYS	-2.39	-0.58	11.60
2025-11-11	KRYS	-2.39	-0.58	11.60
2025-11-12	KRYS	-2.39	-0.58	11.57
2025-11-13	KRYS	-2.39	-0.58	11.57
2025-11-14	KRYS	-2.39	-0.58	11.56
2025-11-17	KRYS	-2.40	0.84	11.56
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

1.73

Avg. EPS Est. Next Quarter

1.46

Insider Transactions

-2.4

Institutional Transactions

0.84

Beta

0.48

Average Sales Estimate Current Quarter

107

Average Sales Estimate Next Quarter

120

Fair Value

189.98

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-53.4

Target Price

222.45

P/E

31.24

Forward P/E

27.28

PEG

0.63

P/S

16.18

P/B

5.3

P/Free Cash Flow

36.47

EPS

6.67

Average EPS Est. Cur. Y

5.86

EPS Next Y. (Est.)

8.62

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

53.3

Relative Volume

0.99

Return on Equity vs Sector %

-12.9

Return on Equity vs Industry %

2.1

EPS 1 7Days Diff

0.8

EPS 1 30Days Diff

0.93

EBIT Estimation

221.4

Krystal Biotech, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 275

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

stock quote shares KRYS – Krystal Biotech, Inc. Stock Price stock today

news today KRYS – Krystal Biotech, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch KRYS – Krystal Biotech, Inc. yahoo finance google finance

stock history KRYS – Krystal Biotech, Inc. invest stock market

stock prices KRYS premarket after hours

ticker KRYS fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: KRYS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y